CNS
Cohen & Steers, Inc.
CNS has lower modeled downside risk, despite its lower overall score.
HOOD
Robinhood Markets, Inc.
HOOD has the edge over CNS overall, supported by stronger modeled upside and stronger valuation.
CNS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CNS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNS.
HOOD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
HOOD's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like HOOD.
CNS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $60.37 | -15% |
| Forward | 20x | $71.42 | — |
| Current | 22x | $71.42 | — |
| Fair | 25x | $80.45 | +13% |
| Expensive | 32x | $105 | +47% |
Historical ranges are pointers, not guarantees.
CNS has the edge over HOOD in the historical PE scenario, which offers more potential upside but is not a forecast.
HOOD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 30x | $81.35 | — |
| Cheap | 37x | $78.84 | -3.1% |
| Current | 38x | $81.35 | — |
| Fair | 51x | $110 | +35% |
| Expensive | 74x | $160 | +96% |
Historical ranges are pointers, not guarantees.
HOOD's PE is in its cheap range at 38x. If earnings grow as analysts expect, today's price would be 30x next year's earnings.
CNS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect CNS's earnings to grow and its profitability to improve, with its revenue holding steady.
HOOD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
HOOD has the edge over CNS on the outlook, with more favorable revenue expectations.
CNS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.64 | +12% |
| Q3 2026 | $3.25 | +1.9% |
| Q2 2026 | $3.25 | +3.2% |
| Q1 2026 | $3.02 | -1.3% |
| Q4 2025 | $2.97 | 0% |
| Q3 2025 | $3.19 | +19% |
| Q2 2025 | $3.15 | +23% |
| Q1 2025 | $3.06 | +19% |
| Q4 2024 | $2.97 | +14% |
CNS earned $3.25 per share over the past year, up 1.9% from the year before.
HOOD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.72 | +26% |
| Q3 2026 | $2.16 | -10% |
| Q2 2026 | $2.26 | +15% |
| Q1 2026 | $2.06 | +18% |
| Q4 2025 | $2.05 | +31% |
| Q3 2025 | $2.40 | +314% |
| Q2 2025 | $1.96 | +513% |
| Q1 2025 | $1.75 | +1150% |
| Q4 2024 | $1.56 | +$2.17 |
HOOD has the edge over CNS on earnings, with more consistent year-over-year improvement.
CNS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $157.4M | +11% |
| Q2 2026 | $152.7M | +12% |
| Q1 2026 | $145.6M | +8.3% |
| Q4 2025 | $143.8M | +2.9% |
| Q3 2025 | $141.7M | +6.4% |
| Q2 2025 | $136.1M | +12% |
| Q1 2025 | $134.5M | +9.6% |
| Q4 2024 | $139.8M | +17% |
CNS's revenue has grown year over year for 10 quarters in a row: $157M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -2.1 points |
| Q2 2026 | 35% | +2.7 points |
| Q1 2026 | 34% | +0.8 points |
| Q4 2025 | 28% | -7.3 points |
| Q3 2025 | 35% | +0.8 points |
| Q2 2025 | 32% | +0.3 points |
| Q1 2025 | 34% | +0.8 points |
| Q4 2024 | 35% | +3.5 points |
CNS's operating margin was 32% last quarter, down 2.1 points from the same quarter a year ago.
HOOD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +12% |
| Q2 2026 | $1.3B | +32% |
| Q1 2026 | $1.1B | +15% |
| Q4 2025 | $1.3B | +27% |
| Q3 2025 | $1.3B | +100% |
| Q2 2025 | $989M | +45% |
| Q1 2025 | $927M | +50% |
| Q4 2024 | $1B | +115% |
HOOD has the edge over CNS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | -5.9 points |
| Q2 2026 | 54% | +9.5 points |
| Q1 2026 | 39% | -1.5 points |
| Q4 2025 | 52% | -3.5 points |
| Q3 2025 | 50% | +26 points |
| Q2 2025 | 45% | +17 points |
| Q1 2025 | 40% | +14 points |
| Q4 2024 | 55% | +49 points |
HOOD has the edge over CNS on profitability, with a higher operating margin.
CNS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $20M | -62% |
| Q1 2026 | -$51.4M | +$58.7M |
| Q4 2025 | $776K | -98% |
| Q3 2025 | $52.6M | +117% |
| Q2 2025 | -$69.8M | -357% |
| Q1 2025 | -$110M | -20588% |
| Q4 2024 | $33.1M | -31% |
| Q3 2024 | $24.2M | -50% |
HOOD has the stronger cash trend. Its trailing FCF is up 1,003% versus its history, compared with CNS at down 71%.
HOOD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +$2.8B |
| Q2 2026 | $720M | -79% |
| Q1 2026 | $2B | +217% |
| Q4 2025 | -$937M | +$463M |
| Q3 2025 | -$1.6B | -187% |
| Q2 2025 | $3.5B | +6398% |
| Q1 2025 | $642M | +$1.3B |
| Q4 2024 | -$1.4B | -246% |
HOOD's free cash flow was $3B over the past year, up 159% from the year before. Free cash flow isn't a meaningful measure for financial services companies like HOOD.
CNS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +253K shares |
| 1 year | +1.1% | +542K shares |
| 3 years | +5% | +2.5M shares |
| 5 years | +5.8% | +2.9M shares |
| Available history | +7% | +3.4M shares |
CNS has 52M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $358,000 |
| Q2 2026 | $394,000 |
| Q1 2026 | $16.9M |
| Q4 2025 | $1.6M |
| Q3 2025 | $258,000 |
| Q2 2025 | $621,000 |
| Q1 2025 | $26M |
| Q4 2024 | $1.5M |
CNS spent $19M buying back its own shares over the past year, down 32% from the year before.
HOOD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -1M shares |
| 1 year | -0.8% | -6.9M shares |
| 3 years | +1.8% | +15.9M shares |
| 5 years | +292% | +679M shares |
| Available history | +7.2% | +60.8M shares |
HOOD has the edge over CNS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25M |
| Q2 2026 | $414M |
| Q1 2026 | $250M |
| Q4 2025 | $100M |
| Q3 2025 | $107M |
| Q2 2025 | $124M |
| Q1 2025 | $322M |
| Q4 2024 | $160M |
HOOD spent $789M buying back its own shares over the past year, up 11% from the year before.
CNS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
CNS has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CNS.
HOOD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.1x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
HOOD has the edge over CNS on leverage, with a lower net debt burden relative to earnings.
CNS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.8 | Neutral |
| Stochastic | 33.9 | Neutral |
CNS's weekly RSI is 45 (neutral) and its Stochastic is 34 (neutral).
HOOD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 9.5 | Oversold |
HOOD's weekly RSI is 41 (neutral) and its Stochastic is 10 (oversold).
CNS PE vs Financial Services Sector
| Metric | CNS | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 13x | 69% above |
| PE % | 33 | 63 | 30 pts below |
CNS has the edge over HOOD on valuation relative to its sector.
HOOD PE vs Financial Services Sector
| Metric | HOOD | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 13x | 189% above |
| PE % | 22 | 66 | 44 pts below |
HOOD is trading at 38x earnings, a 189% premium to the Financial Services sector's median of 13x.
CNS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.8 | 0.5% below |
| 20 week MA | $77.0 | 7.2% below |
| 50 week MA | $71.1 | 0.4% above |
| 100 week MA | $74.1 | 3.6% below |
| 200 week MA | $73.1 | 2.3% below |
CNS's trend is mixed: it's above one of its five weekly moving averages, and 2.3% below its 200-week average.
HOOD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.8 | 17% below |
| 20 week MA | $102.2 | 20% below |
| 50 week MA | $95.4 | 15% below |
| 100 week MA | $88.5 | 8.1% below |
| 200 week MA | $52.1 | 56% above |
HOOD has fallen below most of its moving averages, though it's still 56% above its 200-week average.
CNS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.7 | $73.4 | +17% |
| 2021 | $73.4 | $90.0 | +23% |
| 2022 | $90.0 | $63.2 | -30% |
| 2023 | $63.2 | $75.7 | +20% |
| 2024 | $75.7 | $93.4 | +23% |
| 2025 | $93.4 | $64.2 | -31% |
| 2026 YTD | $64.2 | $71.4 | +11% |
CNS has the edge over HOOD on returns for 2026, with the stronger performance.
HOOD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $35.2 | $18.9 | -46% |
| 2022 | $18.9 | $7.95 | -58% |
| 2023 | $7.95 | $12.7 | +60% |
| 2024 | $12.7 | $39.0 | +206% |
| 2025 | $39.0 | $118.1 | +203% |
| 2026 YTD | $118.1 | $81.4 | -31% |
HOOD's yearly returns have swung widely, from +206% in 2024 to −58% in 2022. It's down 31% so far in 2026.